BioSpace News Archive

Deepcell today announced that it has expanded its commercial team with the appointment of Giovanna Prout as the new VP of Marketing.

Catalent, one of the world’s largest contract research organizations, has begun development of novel solid amorphous dispersion formulations of MB-204, the Company’s novel adenosine A2a receptor antagonist.

The report further provides details about each segments and regions covered in the global Laser Capture Microdissection market. The data has been collected through extensive primary and secondary research and is validated by experts in the industry

G1 Therapeutics, Inc., a commercial-stage oncology company, announced that Jack Bailey and Raj Malik, M.D., G1’s Chief Executive Officer and Chief Medical Officer, respectively, will participate in a fireside chat during the 21st Annual Needham Virtual Healthcare Conference.

Vaccitech plc, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, announced that it has been notified of the commencement of royalty payments relating to commercial sales of Vaxzevria®.

Travere Therapeutics, Inc. announced that the Company will present data from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria, at the Society for Inherited Metabolic Disorders 43rd Annual Meeting, and the 2022 Genetic Metabolic Dieticians International Conference.

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced that a late breaking abstract has been accepted at the upcoming American Diabetes Association 82nd Scientific Sessions.